JAN 21, 2016 9:47 PM PST

Breast milk might make flu shots safe for babies

Influenza causes serious illness among millions of people each year, resulting in 250,000 to 500,000 deaths. Those most at risk include infants younger than six months, because they cannot be vaccinated against the disease.

Now, in a new study with mice, researchers have identified a naturally occurring protein that, when added to the flu vaccine, may offer protection to babies during their first months of life.
 
"We feel that the use of a natural protein would make immunization not only possible but more accepted," says Michael Sherman.

“Influenza vaccine works by stimulating a person’s immune system to make antibodies that attack the flu virus,” says Michael Sherman, professor emeritus of child health at the University of Missouri.

“However, infants younger than six months do not make antibodies when given flu vaccine. This is because the immune systems of these very young babies do not respond to the adjuvant, or additive, within the vaccine that boosts the body’s immune response when confronted with a virus.”

The adjuvant used in most vaccines is aluminum hydroxide, or ALUM. ALUM is an additive that essentially acts as an irritant to attract white blood cells called neutrophils to the vaccination site. Neutrophils secrete the protein lactoferrin, which works with the immune system to impede the virus’s ability to survive in the body.

However, in premature and term infants, ALUM doesn’t make immature immune cells work better. In this very young group, only the smaller amount of naturally occurring lactoferrin found near the vaccination site improves the immune response.

“It is well documented that infants obtain protection against certain infections from nutrients found in breast milk,” Sherman says. “Lactoferrin is the major protein in a mother’s milk and boosts her infant’s immune system to fight infection. In theory, we felt that we could create a vaccine by replacing ALUM with lactoferrin as an additive.”

To test their hypothesis, researchers studied mice vaccinated with either the adjuvant ALUM or lactoferrin. The mice, whose ages approximated those of human infants younger and older than six months, received the H1N1 influenza virus.

As reported in the journal Biochemical and Biophysical Research Communications, lactoferrin worked slightly better than ALUM as an adjuvant and also provided four to five times the protection against influenza, compared to the control group that received an influenza vaccine without an adjuvant.

“Currently, the best protection for neonatal babies is to vaccinate the mother and all those who will have close contact with the infant,” Sherman says. “Our recent study was meant to test the possibility of creating a safe and effective flu vaccine for very high-risk premature infants. Now that we have, we feel that the use of a natural protein would make immunization not only possible but more accepted.”
The researchers will next study lactoferrin’s ability to prevent secondary infections such as pneumonia, as well as the possibility that the protein could be used as an adjuvant in other vaccines.

The study is published in the journal Biochemical and Biophysical Research Communications. The National Institutes of Health, the University of Missouri Research Board, and the Leda J. Sears Trust funded the work. The content of the article is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

This article was originally published on futurity.org.
About the Author
  • Futurity features the latest discoveries by scientists at top research universities in the US, UK, Canada, Europe, Asia, and Australia. The nonprofit site, which launched in 2009, is supported solely by its university partners (listed below) in an effort to share research news directly with the public.
You May Also Like
AUG 24, 2020
Drug Discovery & Development
FDA Grants Emergency Approval for Blood Plasma to Treat COVID-19
AUG 24, 2020
FDA Grants Emergency Approval for Blood Plasma to Treat COVID-19
The US Food and Drug Agency (FDA) has given emergency approval for expanded use of antibody-rich blood plasma to help th ...
SEP 20, 2020
Drug Discovery & Development
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
SEP 20, 2020
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
Biopharmaceutical company Bristol-Myers Squibb has found that a new drug combination can reduce death rates among those ...
OCT 08, 2020
Immunology
Air Pollution Particles Detected in the Placenta, Immune Cells Mop Them Up
OCT 08, 2020
Air Pollution Particles Detected in the Placenta, Immune Cells Mop Them Up
Tiny, black particles much like those found in polluted air have been found in the placentas of pregnant women, as repor ...
OCT 13, 2020
Immunology
Why Halloween Is Extra Scary for Kids With Peanut Allergies
OCT 13, 2020
Why Halloween Is Extra Scary for Kids With Peanut Allergies
A recent study showed that there is an 85 percent spike in peanut allergy anaphylaxis cases on Halloween. The study, per ...
OCT 14, 2020
Immunology
Self-Healing Microcapsules Make Promising Leukemia Vaccines
OCT 14, 2020
Self-Healing Microcapsules Make Promising Leukemia Vaccines
Leukemia is a cancer affecting tissues in the body that produce blood cells, including the bone marrow and the lymphatic ...
NOV 12, 2020
Health & Medicine
Measles Cases and Deaths Surge Worldwide
NOV 12, 2020
Measles Cases and Deaths Surge Worldwide
Today, the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) released a stat ...
Loading Comments...